SZodixStudyAcademic Library
ShelvesOpen access
Study · an open academic library·Metadata from OpenAlex (CC0)·Shelves·OpenAlex metadata, de-duplicated
Defining the concept of fair pricing for medicines
15 references·0 citing·54 second hop
Defining the concept of fair pricing for medicines (2020)Defining the concept of fair pricing for …Estimated costs of production and potential prices for the WHO Essential Medicines List (2018)Estimated costs of production…Defining Elements of Value in Health Care—A Health Economics Approach: An ISPOR Special Task Force Report [3] (2018)Defining Elements of Value in…Towards a coherent global framework for health financing: recommendations and recent developments (2017)Towards a coherent global fra…Toward a Broader Concept of Value: Identifying and Defining Elements for an Expanded Cost-Effectiveness Analysis (2017)Toward a Broader Concept of V…Research and Development Spending to Bring a Single Cancer Drug to Market and Revenues After Approval (2017)Research and Development Spen…Payers’ experiences with confidential pharmaceutical price discounts: A survey of public and statutory health systems in North America, Europe, and Australasia (2017)Payers’ experiences with conf…Cost-related non-adherence to prescribed medicines among older adults: a cross-sectional analysis of a survey in 11 developed countries (2017)Cost-related non-adherence to…Essential medicines for universal health coverage (2016)Essential medicines for unive…Measuring the Value of Prescription Drugs (2015)Measuring the Value of Prescr…Overcoming challenges to sustainable immunization financing: early experiences from GAVI graduating countries (2014)Overcoming challenges to sust…Fair price: research outside marketing (2008)Fair price: research outside …The Price is Unfair! A Conceptual Framework of Price Fairness Perceptions (2004)The Price is Unfair! A Concep…Customer Portfolio Management: Toward a Dynamic Theory of Exchange Relationships (2004)Customer Portfolio Management…Household catastrophic health expenditure: a multicountry analysis (2003)Household catastrophic health…Consumer Perceptions of Price (Un)Fairness (2003)Consumer Perceptions of Price…Economics and Consumer Behavior (1980)Protecting Households From Catastrophic Health Spending (2007)Progress on catastrophic health spending in 133 countries: a retrospective observational study (2017)Catastrophic health spending in Europe: equity and policy implications of different calculation methods (2018)The Nature of the Firm (1937)Institutions, Institutional Change and Economic Performance (1990)Institutions, Institutional Change and Economic Performance (1991)Customer Relationship Dynamics: Service Quality and Customer Loyalty in the Context of Varying Levels of Customer Expertise and Switching Costs (2005)The Value of Different Customer Satisfaction and Loyalty Metrics in Predicting Business Performance (2006)Why build a customer relationship management capability? (2007)Pricing: Making Profitable Decisions (1980)Dimensions of Consumer Expertise (1987)On the Profitability of Long-Life Customers in a Noncontractual Setting: An Empirical Investigation and Implications for Marketing (2000)Reference Price Research: Review and Propositions (2005)Perceptions of Chinese restaurants in the U.S.: What affects customer satisfaction and behavioral intentions? (2008)The influence of perceived food quality, price fairness, perceived value and satisfaction on customers’ revisit and word-of-mouth intentions towards organic food restaurants (2019)The Commitment-Trust Theory of Relationship Marketing (1994)An Integrative Model Of Organizational Trust (1995)'It's Reducing a Human Being to a Percentage' (2018)Advances in Consumer Research (2025)American Society of Clinical Oncology Identifies Five Key Opportunities to Improve Care and Reduce Costs: The Top Five List for Oncology (2012)The Strategy That Will Fix Health Care (2013)American Society of Clinical Oncology Statement: A Conceptual Framework to Assess the Value of Cancer Treatment Options (2015)Addressing the challenge of high-priced prescription drugs in the era of precision medicine: A systematic review of drug life cycles, therapeutic drug markets and regulatory frameworks (2017)Clinical benefit, price and approval characteristics of FDA-approved new drugs for treating advanced solid cancer, 2000–2015 (2017)A Health Economics Approach to US Value Assessment Frameworks—Introduction: An ISPOR Special Task Force Report [1] (2018)The price of innovation: new estimates of drug development costs (2003)Cochrane Handbook for Systematic Reviews of Interventions (2008)Cochrane Handbook for Systematic Reviews of Interventions (2010)Comparing Generic Drug Markets in Europe and the United States: Prices, Volumes, and Spending (2017)The path to longer and healthier lives for all Africans by 2030: the Lancet Commission on the future of health in sub-Saharan Africa (2017)Health systems development in Thailand: a solid platform for successful implementation of universal health coverage (2018)Revisiting the Behavioral Model and Access to Medical Care: Does it Matter? (1995)Prescription drug cost sharing: associations with medication and medical utilization and spending and health. (2007)Pharmaceutical policies: effects of cap and co-payment on rational drug use (2008)The consequences of patient charges for prescription drugs in Canada: a cross-sectional survey (2018)Universal Pharmacare in Canada: A Prescription for Equity in Healthcare (2019)Estimated minimum prices and lowest available national prices for antiobesity medications: Improving affordability and access to treatment (2023)Differential Pricing for Pharmaceuticals: Reconciling Access, R&D and Patents (2003)Linking payment to health outcomes: A taxonomy and examination of performance-based reimbursement schemes between healthcare payers and manufacturers (2010)Risk sharing arrangements for pharmaceuticals: potential considerations and recommendations for European payers (2010)Current prices versus minimum costs of production for CFTR modulators (2022)How to improve R&D productivity: the pharmaceutical industry's grand challenge (2010)The price of drugs for chronic myeloid leukemia (CML) is a reflection of the unsustainable prices of cancer drugs: from the perspective of a large group of CML experts (2013)Innovation in the pharmaceutical industry: New estimates of R&D costs (2016)Estimated Costs of Pivotal Trials for Novel Therapeutic Agents Approved by the US Food and Drug Administration, 2015-2016 (2018)How Much Does It Cost to Research and Develop a New Drug? A Systematic Review and Assessment (2021)Costs of Drug Development and Research and Development Intensity in the US, 2000-2018 (2024)Hedonic Prices and Implicit Markets: Product Differentiation in Pure Competition (1974)Cost-Effectiveness in Health and Medicine (1996)Recommendations for Conduct, Methodological Practices, and Reporting of Cost-effectiveness Analyses (2016)A Health Economics Approach to US Value Assessment Frameworks—Summary and Recommendations of the ISPOR Special Task Force Report [7] (2018)An Overview of Value, Perspective, and Decision Context—A Health Economics Approach: An ISPOR Special Task Force Report [2] (2018)The Economic Burden of Adults with Major Depressive Disorder in the United States (2019) (2023)
this work references cited by second hop

References

  • 2003Household catastrophic health expenditure: a multicountry analysis2,316 cited
  • 2004The Price is Unfair! A Conceptual Framework of Price Fairness Perceptions1,473 cited
  • 2003Consumer Perceptions of Price (Un)Fairness1,077 cited
  • 2016Essential medicines for universal health coverage661 cited
  • 2004Customer Portfolio Management: Toward a Dynamic Theory of Exchange Relationships550 cited
  • 2018Defining Elements of Value in Health Care—A Health Economics Approach: An ISPOR Special Task Force Report [3]544 cited
  • 2017Research and Development Spending to Bring a Single Cancer Drug to Market and Revenues After Approval503 cited
  • 2015Measuring the Value of Prescription Drugs144 cited
  • 2017Payers’ experiences with confidential pharmaceutical price discounts: A survey of public and statutory health systems in North America, Europe, and Australasia117 cited
  • 2017Cost-related non-adherence to prescribed medicines among older adults: a cross-sectional analysis of a survey in 11 developed countries112 cited
  • 2017Toward a Broader Concept of Value: Identifying and Defining Elements for an Expanded Cost-Effectiveness Analysis107 cited
  • 2018Estimated costs of production and potential prices for the WHO Essential Medicines List101 cited
  • 2014Overcoming challenges to sustainable immunization financing: early experiences from GAVI graduating countries53 cited

Only edges whose both ends are imported exist here. Widen the year window, or show the whole map. Back to the work

2017
Towards a coherent global framework for health financing: recommendations and recent developments
34 cited
  • 2008Fair price: research outside marketing13 cited
  • Cited by

    No citing works inside the corpus for this window.